A clinical trial update dated October 30, 2026 reports on a study related to corticotropin, an approved compound. The trial, registered as NCT07460232 and titled "FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease," is listed as an early phase 1 study. Its current status is recruiting.
According to the registration, the study aims to use FET PET/CT imaging as a method to help localize pituitary adenomas in patients with Cushing disease. No outcome data, efficacy findings, or safety results have been posted for this trial at this stage. The update reflects only the trial's design status and current recruitment phase.
Early phase 1 studies are typically focused on initial evaluation of a method or procedure rather than definitive clinical outcomes. As this trial is still in the recruiting stage, no conclusions about the imaging approach's performance can be drawn from this update. Further updates may follow as the trial progresses through subsequent phases.
Readers interested in corticotropin and its broader clinical and regulatory context can consult the compound overview for additional background.